{
  "@context": "aku-v2",
  "@type": "concept",
  "@id": "wsmg:health-sciences:medicine:surgery:vascular:pharmacology:pharm-004",
  "metadata": {
    "version": "2.1.0",
    "created": "2026-01-08T20:35:00.000Z",
    "modified": "2026-01-08T20:35:00.000Z",
    "contributors": ["copilot-agent", "vascular-surgery-sme"],
    "confidence": 0.93,
    "status": "pending-quality-check",
    "language": "en",
    "licenses": ["CC-BY-4.0"]
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology",
    "subdomain": "anticoagulation",
    "type": "definition",
    "difficulty": "intermediate",
    "importance": "critical",
    "isNativeDomain": true,
    "board_yield": "HIGH"
  },
  "content": {
    "title": "Factor Xa Inhibitors",
    "summary": "Factor Xa inhibitors are direct oral anticoagulants (DOACs) that selectively inhibit activated factor X, a key enzyme in the coagulation cascade. They offer predictable anticoagulation without routine monitoring and are widely used for VTE and stroke prevention.",
    "definition": "A class of anticoagulants that directly and selectively inhibit factor Xa, blocking the conversion of prothrombin to thrombin in the common pathway of coagulation",
    "mechanism_of_action": {
      "factor_Xa_role": "Key enzyme catalyzing prothrombin → thrombin conversion",
      "amplification_effect": "1 molecule factor Xa generates ~1000 thrombin molecules",
      "direct_inhibition": {
        "binding": "Binds to active site of factor Xa",
        "reversible": "Competitive, reversible inhibition",
        "no_cofactor": "Does not require antithrombin"
      },
      "inhibits_both": "Free Xa and prothrombinase-bound Xa"
    },
    "specific_agents": {
      "rivaroxaban": {
        "trade_name": "Xarelto",
        "dosing": "10mg, 15mg, 20mg once or twice daily depending on indication",
        "bioavailability": "66-100% (higher with food for 15mg/20mg doses)",
        "half_life": "5-9 hours (11-13 hours in elderly)",
        "metabolism": "Hepatic (CYP3A4, CYP2J2) and renal",
        "renal_clearance": "~33%",
        "dose_adjustment": {
          "renal": "Avoid if CrCl <15; dose adjust 15-50 mL/min for some indications",
          "hepatic": "Avoid in moderate-severe (Child-Pugh B/C)"
        },
        "indications": ["AF stroke prevention", "VTE treatment", "VTE prophylaxis", "CAD/PAD (2.5mg BID with aspirin)"],
        "food_requirement": "15mg and 20mg doses should be taken with food"
      },
      "apixaban": {
        "trade_name": "Eliquis",
        "dosing": "2.5mg or 5mg twice daily",
        "bioavailability": "~50%",
        "half_life": "8-15 hours",
        "metabolism": "Primarily hepatic (CYP3A4), some renal",
        "renal_clearance": "~27%",
        "dose_adjustment": {
          "renal": "2.5mg BID if 2 of: age ≥80, weight ≤60kg, Cr ≥1.5",
          "hepatic": "Avoid in severe (Child-Pugh C)"
        },
        "indications": ["AF stroke prevention", "VTE treatment", "VTE prophylaxis"],
        "advantages": ["Lowest bleeding risk among DOACs", "Least renal dependence"]
      },
      "edoxaban": {
        "trade_name": "Savaysa/Lixiana",
        "dosing": "60mg or 30mg once daily",
        "bioavailability": "62%",
        "half_life": "10-14 hours",
        "metabolism": "Minimal hepatic, primarily renal",
        "renal_clearance": "~50%",
        "dose_adjustment": {
          "renal": "30mg if CrCl 15-50; avoid >95 (less effective)",
          "hepatic": "Avoid in moderate-severe"
        },
        "indications": ["AF stroke prevention", "VTE treatment after parenteral anticoagulation"],
        "unique": "Paradoxically less effective in high CrCl (>95 mL/min)"
      },
      "betrixaban": {
        "trade_name": "Bevyxxa",
        "dosing": "160mg day 1, then 80mg once daily",
        "half_life": "19-27 hours (longest)",
        "metabolism": "Minimal hepatic, primarily biliary",
        "renal_clearance": "~18%",
        "indications": "Extended VTE prophylaxis in hospitalized medical patients",
        "status": "Limited availability, discontinued in some markets"
      }
    },
    "clinical_applications": {
      "VTE_treatment": {
        "role": "First-line for most DVT/PE",
        "duration": "3 months to indefinite depending on risk",
        "advantages": "No bridging with heparin needed (except edoxaban)"
      },
      "AF_stroke_prevention": {
        "role": "Preferred over warfarin for most patients",
        "CHA2DS2_VASc": "Indicated when score ≥2 (men) or ≥3 (women)",
        "advantages": "Lower intracranial bleeding, no INR monitoring"
      },
      "VTE_prophylaxis": {
        "post_orthopedic": "Approved for hip/knee replacement",
        "medical": "Rivaroxaban, betrixaban for high-risk medical patients"
      },
      "CAD_PAD": {
        "rivaroxaban_low_dose": "2.5mg BID with aspirin per COMPASS trial",
        "indication": "Stable CAD or PAD for secondary prevention"
      }
    },
    "laboratory_considerations": {
      "no_routine_monitoring": "Main advantage; fixed dosing",
      "when_to_measure": [
        "Bleeding or thrombosis on therapy",
        "Urgent surgery",
        "Suspected overdose",
        "Assessing compliance"
      ],
      "assays": {
        "anti_Xa_assay": "Drug-specific calibration; most accurate",
        "PT_INR": "Variable prolongation; rivaroxaban > apixaban effect",
        "aPTT": "Less sensitive, not reliable for monitoring"
      }
    },
    "drug_interactions": {
      "P_gp_inhibitors_inducers": "Affect all factor Xa inhibitors",
      "CYP3A4_interactions": "Primarily rivaroxaban, apixaban",
      "dual_pathway": "Combined P-gp AND CYP3A4 inhibition increases levels most",
      "examples": {
        "increase_levels": ["Ketoconazole", "Ritonavir", "Clarithromycin"],
        "decrease_levels": ["Rifampin", "Phenytoin", "Carbamazepine"]
      }
    },
    "reversal": {
      "andexanet_alfa": {
        "mechanism": "Recombinant modified factor Xa decoy",
        "indication": "Life-threatening bleeding on factor Xa inhibitor",
        "dose": "Weight and drug-specific bolus and infusion",
        "limitations": "Expensive, potential thrombotic risk"
      },
      "PCC": {
        "4_factor_PCC": "Off-label but recommended if andexanet unavailable",
        "dose": "25-50 units/kg"
      },
      "supportive": ["Discontinue drug", "Local hemostasis", "Transfusion support"]
    }
  },
  "skos": {
    "prefLabel": {"@language": "en", "@value": "Factor Xa Inhibitors"},
    "altLabel": [
      {"@language": "en", "@value": "Direct factor Xa inhibitors"},
      {"@language": "en", "@value": "Factor Xa antagonists"},
      {"@language": "en", "@value": "Xabans"}
    ],
    "definition": {"@language": "en", "@value": "Anticoagulants that directly and selectively inhibit factor Xa in the coagulation cascade"},
    "notation": "pharm-004"
  },
  "relationships": {
    "skos:broader": [{"@id": "wsmg:health-sciences/medicine/surgery/vascular/pharmacology", "skos:prefLabel": "Vascular Pharmacology"}],
    "skos:related": [
      {"@id": "wsmg:health-sciences:medicine:surgery:vascular:pharmacology:pharm-003", "skos:prefLabel": "Direct Thrombin Inhibitors"},
      {"@id": "wsmg:health-sciences:medicine:surgery:vascular:pharmacology:pharm-006", "skos:prefLabel": "Reversal Agents"}
    ]
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codingSystem": "ATC",
      "codeValue": "B01AF",
      "description": "Direct factor Xa inhibitors"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "MeSH",
      "codeValue": "D065427",
      "uri": "http://id.nlm.nih.gov/mesh/D065427",
      "description": "Factor Xa Inhibitors"
    }
  ],
  "pedagogical": {
    "learning_objectives": [
      "Explain the mechanism of action of factor Xa inhibitors",
      "Compare pharmacokinetic properties of rivaroxaban, apixaban, and edoxaban",
      "List FDA-approved indications for factor Xa inhibitors",
      "Identify situations requiring dose adjustment",
      "Describe reversal options including andexanet alfa"
    ],
    "clinical_pearls": [
      "Apixaban has lowest bleeding risk and least renal dependence",
      "Rivaroxaban 15mg/20mg must be taken with food for absorption",
      "Edoxaban is LESS effective in high CrCl (>95 mL/min) - don't use",
      "Anti-Xa assay (drug-specific calibration) is most accurate",
      "COMPASS: Rivaroxaban 2.5mg BID + aspirin reduces MACE in stable CAD/PAD"
    ],
    "estimated_time": "30min",
    "target_audience": ["vascular_surgery_residents", "cardiology", "pharmacy", "internal_medicine"]
  }
}
